Weekly News Recap #Phispers | PharmaCompass.com

Novo bets up to US$ 4.6 bn on AI drug development, expands deal with Valo Health; WuXi sells Irish vaccine plant to Merck

As the embattled WuXi Biologics faces increasing pressure from the impending US Biosecure Act, it has decided to sell its vacci...

Impressions : 751

Lilly’s Zepbound becomes first FDA-approved therapy for sleep apnea; Novo wins nod for daily hemophilia shot

This week’s Phispers is a double bill with news from the last two weeks. Through much of December, the US Food and Drug A...

Impressions : 891

Novo invests US$ 1.2 bn in new rare disease plant in Denmark; FDA approves two drugs for atopic dermatitis

As the year draws to a close, the US Food and Drug Administration (FDA) has been approving drugs at a feverish pace. It approve...

Impressions : 726

Lilly, Amgen inject billions into manufacturing; GSK’s Blenrep bests world’s top-selling myeloma drug

In Phispers this week, Eli Lilly announced an investment of US$ 3 billion towards building a new plant in Wisconsin (US) to me...

Impressions : 10288

Novartis snaps up PTC’s Huntington’s disease program in US$ 2.9 bn deal; Sanofi to set up insulin facility in China

In Phispers this week, we bring you news of how political changes in the US could impact the pharma industry. Big Pharma has r...

Impressions : 762

Sarepta inks US$ 11 bn RNA deal with Arrowhead; Roche expands CAR-T arsenal; Novartis buys Kate for US$ 1 bn

The week saw three large deals signed in promising fields. First, Sarepta Therapeutics signed a US$ 11.4 billion deal with Ar...

Impressions : 1142

Merck inks US$ 3.3 bn cancer deal with LaNova; vaccine makers’ stocks tumble after Trump picks RFK Jr to head HHS

This week, Merck struck a strategic US$ 3.3 billion deal with LaNova Medicines for a promising cancer drug, and also demonstr...

Impressions : 1045

Astra invests US$ 2 bn in US R&D; key AbbVie asset from US$ 8.7 bn Cerevel buy flunks phase 2 trials

This week’s Phispers is packed with news about deals. First, AstraZeneca announced a US$ 2 billion investment in the...

Impressions : 648

Astra faces probe in China; AbbVie, EvolveImmune ink potential US$ 1.4 bn deal; EC levies US$ 503 mn fine on Teva

In this week’s Phispers, AstraZeneca faces a major crisis in China as its president Leon Wang is under investigation in w...

Impressions : 858

AbbVie strengthens Alzheimer’s pipeline with US$ 1.4 bn Aliada buyout; Roche expands gene therapy pact with Dyno

This week’s Phispers is packed with latest developments in the field of Alzheimer’s disease, owing to a conference ...

Impressions : 773

Sanofi to sell 50% stake in Opella to CD&R, to retain French workforce; AbbVie bags FDA nod for Parkinson’s therapy Vyalev

In this week’s Phispers, Sanofi has entered into exclusive talks with US private equity firm CD&R to sell a controlling 5...

Impressions : 876

Lundbeck acquires Longboard for US$ 2.6 billion; Roche’s Itovebi bags FDA nod for breast cancer

This week’s is a double dose Phispers, as we return from a one-week break due to CPhI Worldwide. The fortnight saw severa...

Impressions : 946

BMS med wins landmark FDA nod for schizophrenia; Sanofi’s Dupixent approved to treat COPD

In this week’s Phispers, the US Food and Drug Administration (FDA) approved Bristol Myers Squibb’s groundbreaking s...

Impressions : 892

Sanofi gets two bids valuing its consumer unit at US$ 17 bn; Pfizer pulls SCD drug from market

In news this week, Sanofi is considering the sale of its consumer health unit and has received binding bids valuing the divisi...

Impressions : 1154

FDA panel votes against Intercept’s liver med Ocaliva; Lilly’s Ebglyss wins approval for eczema

Intercept Pharmaceuticals faced a major setback as a US Food and Drug Administration (FDA) panel voted against the confirmato...

Impressions : 996

GSK’s COPD, long-acting asthma drugs score late-stage wins; Novo’s weight-loss drug Saxenda found to be safe in kids

GSK scored a significant late-stage win with its asthma drug Nucala in treating chronic obstructive pulmonary disease (COPD). I...

Impressions : 724

FDA approves Emergent’s smallpox vaccine for mpox; Lilly inks up to US$ 1 bn deal with Haya to target obesity

This week saw the US Food and Drug Administration (FDA) respond to the global monkeypox (mpox) public health emergency by expan...

Impressions : 1061

Lilly, Pfizer move to sell drugs directly to consumers; blast at Indian drug factory kills 17

An Indian factory that makes drugs for export to the US and other Western nations saw an explosion, caused by a chemical solven...

Impressions : 1567

IRA price talks conclude, three meds dominate savings; Gilead’s Livdelzi from CymaBay buyout gets FDA okay

This week, the Biden-Harris Administration said it has concluded price negotiations for 10 drugs under the Inflation Reduction ...

Impressions : 711

FDA rejects first MDMA therapy to treat PTSD; Merck, Curon ink up to US$ 1.3 bn deal for next-gen bispecific antibody

The US Food and Drug Administration (FDA) has declined to approve an MDMA-assisted therapy from Lykos Therapeutics to treat pos...

Impressions : 1405

FDA approves first ever T-cell receptor gene therapy from Adaptimmune, Servier’s brain tumor pill

This week, Adaptimmune clinched gold when it secured the first-ever US Food and Drug Administration (FDA) approval for a T-cell...

Impressions : 877

Boehringer boosts immune-oncology pipeline with US$ 1.3 bn Nerio buy; Pfizer adds US$ 1 bn to 2024 outlook

This week, the world’s largest private pharma company, Boehringer Ingelheim, acquired Nerio Therapeutics for up to US$ 1....

Impressions : 782

Merck’s RSV jab shows efficacy in infants; Novo-Lilly weight loss rivalry intensifies as China okays tirzepatide

This was a week when the US President Joe Biden ended his reelection bid, after giving America the Inflation Reduction Act that...

Impressions : 1005

US Senate passes bipartisan bill to cut pharma patent abuses; Ipsen inks another ADC deal

This week, a bill heralded as “critical” to help “end anti-competitive practices” was passed by the US ...

Impressions : 1241

Lilly to acquire IBD drug developer Morphic for US$ 3.2 bn; Pfizer’s R&D chief to step down

This week saw Eli Lilly strike yet another deal as it announced the acquisition of Morphic Holding for about US$ 3.2 billion, t...

Impressions : 1006

Lilly’s Alzheimer’s drug gets FDA nod; GSK buys rights to mRNA vaccines from Curevac for US$ 1.56 bn

This week, the US Food and Drug Administration (FDA) finally approved Eli Lilly’s Alzheimer’s drug donanemab after ...

Impressions : 836

Novo invests US$ 4.1 bn to boost Wegovy, Ozempic supply; Verona’s COPD therapy bags FDA nod

This week saw a couple of developments in the lucrative US market for glucagon-like peptide-1 (GLP-1) drugs that treat diabetes...

Impressions : 1015

Merck wins FDA nod for pneumococcal vaccine; Roche partners Ascidian to develop novel gene therapies

This week saw the US Food and Drug Administration (FDA) approve Merck’s next-generation pneumococcal vaccine for adults. ...

Impressions : 1104

NEWS

DRUGS & DEVELOPMENTS

MARKET INTEL by PharmaCompass